哌拉西林-阿维巴坦对多重耐药伯克霍尔德菌复合群和唐菖蒲伯克霍尔德菌囊性纤维化分离株具有高效力
本研究针对囊性纤维化患者中多重耐药伯克霍尔德菌复合群(Bcc)和唐菖蒲伯克霍尔德菌(B. gladioli)感染,测试了哌拉西林-阿维巴坦及哌拉西林-他唑巴坦联合头孢他啶-阿维巴坦的体外活性。结果显示,这些组合使99%对头孢他啶-阿维巴坦不耐药的分离株恢复敏感性,阿维巴坦强效抑制PenA1(Kiapp=0.5 μM),哌拉西林抑制AmpC1(Kiapp=2.6 μM),且不诱导blapenA1和blaampC1表达,提示可能作为挽救治疗。
要点
- 哌拉西林-阿维巴坦对99%的头孢他啶-阿维巴坦不耐药Bcc和B. gladioli分离株恢复敏感性。
- 哌拉西林-他唑巴坦联合头孢他啶-阿维巴坦同样恢复99%分离株的敏感性。
- 阿维巴坦强效抑制PenA1(Kiapp=0.5 μM),哌拉西林抑制AmpC1(Kiapp=2.6 μM)。
核心结论
- 哌拉西林-阿维巴坦及哌拉西林-他唑巴坦联合头孢他啶-阿维巴坦在体外对头孢他啶-阿维巴坦不耐药的Bcc和B. gladioli临床分离株具有高度活性。
研究设计与样本
- 对Bcc和B. gladioli临床及对照分离株进行抗菌药物敏感性试验。
- 对纯化的Burkholderia multivorans ATCC 17616的PenA1和AmpC1 β-内酰胺酶进行生化分析。
- 对经不同β-内酰胺或β-内酰胺-β-内酰胺酶抑制剂组合诱导的B. multivorans细胞提取物进行等电聚焦和免疫印迹。
主要发现
- 哌拉西林-阿维巴坦和哌拉西林-他唑巴坦联合头孢他啶-阿维巴坦使99%的测试分离株恢复敏感性。
- 阿维巴坦对PenA1的抑制常数Kiapp为0.5 μM,哌拉西林对AmpC1的Kiapp为2.6 μM。
- 哌拉西林、他唑巴坦、头孢他啶、阿维巴坦及其组合在B. multivorans ATCC 17616背景中不诱导blapenA1和blaampC1表达。
- blapenA1不诱导及阿维巴坦对PenA1的有效灭活可能是敏感性的主要贡献因素。
关键数值与推荐
- 哌拉西林-阿维巴坦和哌拉西林-他唑巴坦联合头孢他啶-阿维巴坦对99%的头孢他啶-阿维巴坦不耐药Bcc和B. gladioli分离株恢复敏感性。
- 阿维巴坦抑制PenA1的Kiapp为0.5 μM;哌拉西林抑制AmpC1的Kiapp为2.6 μM。
临床怎么用
- 对于囊性纤维化患者多重耐药Bcc和B. gladioli感染,哌拉西林-他唑巴坦联合头孢他啶-阿维巴坦可能作为挽救治疗,但需体内验证。
局限性
- 研究为体外实验,需体内验证哌拉西林-他唑巴坦联合头孢他啶-阿维巴坦的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In persons with cystic fibrosis (CF), airway infection with Burkholderia cepacia complex (Bcc) species or Burkholderia gladioli presents a significant challenge due to inherent resistance to multiple antibiotics. Two chromosomally encoded inducible β-lactamases, a Pen-like class A and AmpC are produced in Bcc and B. gladioli Previously, ceftazidime-avibactam demonstrated significant potency against Bcc and B. gladioli isolated from the sputum of individuals with CF; however, 10% of the isolates tested resistant to ceftazidime-avibactam. Here, we describe an alternative antibiotic combination to overcome ceftazidime-avibactam resistance. Antimicrobial susceptibility testing was performed on Bcc and B. gladioli clinical and control isolates. Biochemical analysis was conducted on purified PenA1 and AmpC1 β-lactamases from Burkholderia multivorans ATCC 17616. Analytic isoelectric focusing and immunoblotting were conducted on cellular extracts of B. multivorans induced by various β-lactams or β-lactam-β-lactamase inhibitor combinations. Combinations of piperacillin-avibactam, as well as piperacillin-tazobactam plus ceftazidime-avibactam (the clinically available counterpart), were tested against a panel of ceftazidime-avibactam nonsusceptible Bcc and B. gladioli The piperacillin-avibactam and piperacillin-tazobactam-ceftazidime-avibactam combinations restored susceptibility to 99% of the isolates tested. Avibactam is a potent inhibitor of PenA1 (apparent inhibitory constant [Kiapp] = 0.5 μM), while piperacillin was found to inhibit AmpC1 (Kiapp = 2.6 μM). Moreover, piperacillin, tazobactam, ceftazidime, and avibactam, as well as combinations thereof, did not induce expression of blapenA1 and blaampC1 in the B. multivorans ATCC 17616 background. When ceftazidime-avibactam is combined with piperacillin-tazobactam, the susceptibility of Bcc and B. gladioli to ceftazidime and piperacillin is restored in vitro Both the lack of blapenA1 induction and potent inactivation of PenA1 by avibactam likely provide the major contributions toward susceptibility. With in vivo validation, piperacillin-tazobactam-ceftazidime-avibactam may represent salvage therapy for individuals with CF and highly drug-resistant Bcc and B. gladioli infections.
引用
- Zeiser ET, Becka SA, Wilson BM, et al. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates. J Clin Microbiol. 2019. PMID: 31167848. doi:10.1128/JCM.00181-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。